Table 1. Demographic and clinical characteristics data of subjects in the study cohort.
| Subjects | Viral Load (Copies/ml) | CD4 Count (per µl) | Sexa | Age Group | Birth Placeb | HIV-1 Subtype | Duration of Infection (yr) | ART statusc |
| 013 | 6,080 | 282 | M | 40–60 | N. A | B | 2.0 | ART naive |
| 020 | 3,406 | 587 | M | 18–25 | N. A | B | 5.5 | ART intermittence |
| 022 | 9,356 | 250 | M | 40–60 | S. A | B | 8.0 | ART naive |
| 024 | 38,658 | 316 | M | >60 | N. A | B | 6.5 | ART naive |
| 029 | 43,750 | 307 | M | 25–40 | Africa | C | 4.5 | ART naive |
| 036 | 5,748 | 535 | F | 18–25 | N. A | B | 1.0 | ART naive |
| 038 | 46,896 | 450 | M | 25–40 | N.A | B | 5.0 | ART naive |
| 039 | 2,378 | 108 | M | 40–60 | N.A | B | 20.0 | Kaletra, Truvada |
| 042 | 1,448 | 484 | F | 40–60 | N.A | B | 18.0 | ART naive |
| 049 | 7,352 | 185 | M | 25–40 | S.A | B | 0.2 | ART naive |
| 058 | 2,278 | 499 | M | 25–40 | N.A | B | 5.0 | Kivexa, ATV, RTV |
| 064 | 35,774 | 444 | M | 40–60 | N.A | B | 0.1 | ART naive |
| 065 | 14,240 | 324 | M | 40–60 | N.A | B | 4.5 | ART naive |
| 067 | 11,076 | 256 | M | 40–60 | N.A | B | 14.0 | ART naive |
| 080 | 4,462 | 208 | M | 25–40 | S.A | B | 0.5 | ART naive |
| 083 | 504 | 49 | M | 40–60 | N.A | B | 14.0 | DRV, RTV, ETR, Truvada |
| 086 | 50,192 | 115 | M | 40–60 | N.A | B | 14.0 | ART intermittence |
Abbreviations:
a
: M: Male; F: Female.
b
: N.A: North America; S.A: South America;
c
: ATV: Reyataz; RTV: Norvir; DRV: Darunavir; ETR: Etravirine; Truvada.